We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-2.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$415M
AUM Growth
-$201M
(-33%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-38.55%
Top 10 Holdings %
Top 10 Hldgs %
36.85%
Holding
112
New
24
Increased
13
Reduced
25
Closed
42
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
+$17.7M |
| 2 |
Merck
MRK
|
+$13.8M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$9.02M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$8.34M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$7.95M |
Top Sells
| 1 |
Edwards Lifesciences
EW
|
+$10.2M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$9.85M |
| 3 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$7.64M |
| 4 |
Pacific Biosciences
PACB
|
+$6.72M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$6.65M |
Sector Composition
| 1 | Healthcare | 73.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVRO
26
DELISTED
NEVRO CORP.
NVRO
| $6.54M | 1.57% |
90,000
+30,000
| +50% | +$2.57M |
|
27
CALL
Boston Scientific
BSX
$65.4B
| $6.49M | 1.56% |
300,000
-150,000
| -33% | -$3.27M |
|
|
IMMU
28
DELISTED
Immunomedics Inc
IMMU
| $6.24M | 1.5% |
1,700,000
-300,000
| -15% | -$888K |
|
29
CALL
Puma Biotechnology
PBYI
$434M
| $6.14M | 1.48% |
+200,000
| New | +$8.65M |
|
|
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.97M | 1.44% |
575,000
| – | – |
|
31
Bristol-Myers Squibb
BMY
$124B
| $5.84M | 1.41% |
+100,000
| New | +$5.47M |
|
32
Agios Pharmaceuticals
AGIO
$2.36B
| $5.84M | 1.41% |
+140,000
| New | +$7.35M |
|
33
Perrigo
PRGO
$1.48B
| $5.83M | 1.4% |
+70,000
| New | +$6.07M |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| $5.75M | 1.38% |
+475,000
| New | +$4.96M |
|
|
NSTG
35
DELISTED
NanoString Technologies, Inc.
NSTG
| $5.58M | 1.34% |
250,000
-125,000
| -33% | -$2.68M |
|
36
CALL
Sarepta Therapeutics
SRPT
$1.82B
| $5.49M | 1.32% |
200,000
-150,000
| -43% | -$6.02M |
|
37
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
| $4.35M | 1.05% |
+46,400
| New | +$4.43M |
|
38
Biogen
BIIB
$30.4B
| $4.25M | 1.02% |
15,000
| – | – |
|
|
ENDP
39
DELISTED
Endo International plc
ENDP
| $4.12M | 0.99% |
+250,000
| New | +$4.4M |
|
|
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.05M | 0.98% |
365,000
+207,038
| +131% | +$1.95M |
|
|
WMGI
41
DELISTED
Wright Medical Group Inc
WMGI
| $4.02M | 0.97% |
175,000
-250,000
| -59% | -$5.81M |
|
|
ONCE
42
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $3.99M | 0.96% |
+80,000
| New | +$4.29M |
|
|
ENTL
43
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $3.79M | 0.91% |
200,000
| – | – |
|
|
QGENF
44
DELISTED
QIAGEN NV
QGENF
| $3.78M | 0.91% |
135,000
-65,000
| -33% | -$1.82M |
|
45
Neurogene
NGNE
$744M
| $3.71M | 0.89% |
11,250
-1,250
| -10% | -$336K |
|
46
iRhythm Holdings
IRTC
$3.64B
| $3.46M | 0.83% |
+115,182
| New | +$3.1M |
|
47
Aclaris Therapeutics
ACRS
$793M
| $3.26M | 0.78% |
120,000
-55,000
| -31% | -$1.4M |
|
48
Acadia Pharmaceuticals
ACAD
$4.38B
| $2.88M | 0.69% |
100,000
-100,000
| -50% | -$2.65M |
|
49
IRIDEX
IRIX
$16.3M
| $2.81M | 0.68% |
+200,000
| New | +$2.84M |
|
|
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
| $2.73M | 0.66% |
225,000
-100,000
| -31% | -$1.1M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q4 2016 Portfolio in Review
As of Q4 2016, Ghost Tree Capital held 112 positions worth $415M, down 33% from $617M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ghost Tree Capital withdrew a net $160M in Q4 2016, closing 42 positions and reducing 25 holdings. Its most notable exit was Edwards Lifesciences, an estimated $10.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 51% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in Shire pic worth $17M.
- Ghost Tree Capital's largest Q4 2016 buy was Shire pic: 100,000 shares worth $17M.
- Ghost Tree Capital added most to AveXis, Inc. Common Stock in Q4 2016, an estimated $7.93M increase.
- Ghost Tree Capital's biggest Q4 2016 reduction was Clovis Oncology, Inc., cutting an estimated $9.85M.
- Ghost Tree Capital fully exited Edwards Lifesciences in Q4 2016, selling an estimated $10.2M.
- Ghost Tree Capital's ten largest holdings make up 37% of its $415M portfolio in Q4 2016.
- Ghost Tree Capital opened 24 new positions and closed 42 in Q4 2016.
- Ghost Tree Capital's portfolio value fell 33% quarter-over-quarter to $415M.
Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.